Encompass Health
EHC
122.48
-2.21
-1.77%
Encompass Health
US · EHC
#1326 by market cap
Listed 1970
122.48
-2.21
-1.77%
Live - 5344 symbols - heartbeat 467s ago
· 2026-10-08 07:40
Pre-market
122.48
0.00%
After-hours
122.40
-0.07%
- Market cap
- 12.08B
- P/E (TTM)i
- 19.95
- P/Bi
- 4.65
- EPSi
- 5.54
- Div yieldi
- 0.62%
- 52W posi
- 86%
Reader sentiment
Are you bullish or bearish on EHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.49, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +10.46% YoY
Margins
- Gross margin
- 95.71%
- Operating margin
- 17.74%
- Net margin
- 9.51%
Key ratios & quality
- Enterprise valuei
- 14.53B
- PEG ratioi
- 0.72
- Altman Z-Scorei
- 3.49
PEG uses trailing P/E against the 3-year net income growth rate (27.84%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.28B | 4.61B | 3.57B | 4.01B | 4.35B | 4.80B | 5.37B | 5.94B |
| Gross profit | 4.12B | 4.44B | 3.40B | 3.83B | 4.15B | 4.58B | 5.13B | 5.68B |
| Selling & admin expenses | 2.65B | 2.90B | 2.12B | 2.36B | 2.60B | 2.86B | 3.17B | 3.41B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 681.60M | 692.50M | 530.40M | 659.40M | 630.20M | 731.80M | 864.50M | 1.05B |
| Pretax profit | 493.20M | 562.30M | 352.90M | 505.00M | 450.80M | 607.20M | 749.60M | 953.00M |
| Tax | 118.90M | 115.90M | 74.70M | 101.90M | 100.10M | 132.20M | 150.20M | 192.90M |
| Net profit | 375.40M | 445.80M | 368.80M | 517.20M | 365.90M | 463.00M | 596.60M | 759.10M |
| Basic EPS | 3 | 4 | 3 | 4 | 3 | 4 | 5 | 6 |
| Diluted EPS | 2.93 | 3.61 | 2.85 | 4.11 | 2.70 | 3.47 | 4.46 | 5.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.46B | 1.46B | 1.48B | 1.54B | 1.59B | 1.60B |
| Gross profit | 1.39B | 1.39B | 1.41B | 1.48B | 1.52B | 1.53B |
| Selling & admin expenses | 829.50M | 841.80M | 855.80M | 884.00M | 891.50M | 897.60M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 267.00M | 259.10M | 243.60M | 283.40M | 301.60M | 288.40M |
| Pretax profit | 238.60M | 236.80M | 219.90M | 257.70M | 288.70M | 261.60M |
| Tax | 41.60M | 51.00M | 44.90M | 55.40M | 56.40M | 53.60M |
| Net profit | 196.50M | 184.90M | 174.60M | 203.10M | 248.20M | 207.40M |
| Basic EPS | 2 | 1 | 1 | 1 | 2 | 2 |
| Diluted EPS | 1.48 | 1.39 | 1.24 | 1.43 | 1.93 | 1.54 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 662.10M | 755.80M | 948.60M | 921.40M | 717.20M | 841.80M | 886.90M | 905.90M |
| Cash & ST investments | 69.20M | 94.80M | 224.00M | 49.40M | 21.80M | 69.10M | 85.40M | 72.20M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 5.18B | 6.08B | 6.45B | 6.86B | 5.64B | 6.10B | 6.53B | 7.09B |
| Total current liabilities | 672.50M | 721.00M | 717.30M | 748.80M | 575.90M | 656.40M | 841.00M | 836.40M |
| Short-term debt | 35.80M | 79.70M | 83.10M | 61.30M | 50.80M | 48.90M | 164.90M | 70.10M |
| Long-term debt | 2.48B | 3.02B | 3.25B | 3.24B | 2.74B | 2.69B | 2.36B | 2.45B |
| Total liabilities | 3,356,300,000.00 | 4,148,000,000.00 | 4,444,300,000.00 | 4,465,700,000.00 | 3,774,600,000.00 | 3,805,200,000.00 | 3,685,500,000.00 | 3,813,900,000.00 |
| Total equity | 1.82B | 1.93B | 2.00B | 2.40B | 1.86B | 2.30B | 2.85B | 3.28B |
| Retained earnings | -885.20M | -526.50M | -242.30M | 141.80M | 115.70M | 406.50M | 796.70M | 1.29B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 910.90M | 918.10M | 869.80M | 905.90M | 1.03B | 1.04B |
| Cash & ST investments | 95.80M | 99.10M | 48.70M | 72.20M | 110.50M | 107.70M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 6.64B | 6.79B | 6.87B | 7.09B | 7.31B | 7.46B |
| Total current liabilities | 856.00M | 865.10M | 762.00M | 836.40M | 876.80M | 873.40M |
| Short-term debt | 165.40M | 164.70M | 64.90M | 70.10M | 69.80M | 63.40M |
| Long-term debt | 2.33B | 2.32B | 2.39B | 2.45B | 2.53B | 2.60B |
| Total liabilities | 3,703,700,000.00 | 3,697,500,000.00 | 3,679,400,000.00 | 3,813,900,000.00 | 3,946,000,000.00 | 3,996,400,000.00 |
| Total equity | 2.94B | 3.09B | 3.19B | 3.28B | 3.37B | 3.46B |
| Retained earnings | 930.80M | 1.06B | 1.16B | 1.29B | 1.46B | 1.60B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 762.40M | 635.30M | 704.70M | 715.80M | 705.80M | 850.80M | 1.00B | 1.18B |
| Depreciation & amortization | 199.70M | 218.70M | 203.00M | 219.60M | 243.60M | 273.90M | 299.60M | 327.90M |
| Free cash flow | 486.20M | 231.20M | 300.10M | 170.10M | 121.70M | 267.70M | 360.30M | 439.20M |
| Dividends paid | -100.80M | -108.70M | -111.80M | -112.20M | -99.00M | -60.40M | -62.80M | -71.10M |
| Stock buybacks / issuance | 0 | -45.90M | -6.10M | -- | 0 | 0 | -31.10M | -158.00M |
| Ending cash balance | 133.50M | 159.60M | 310.90M | 120.30M | 53.40M | 104.20M | 123.10M | 102.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 288.60M | 270.20M | 270.80M | 346.00M | 313.10M | 282.60M |
| Depreciation & amortization | 79.20M | 79.90M | 82.40M | 86.40M | 87.30M | 90.40M |
| Free cash flow | 125.50M | 113.30M | 83.70M | 116.70M | 150.70M | 62.30M |
| Dividends paid | -18.00M | -17.10M | -17.00M | -19.00M | -20.30M | -18.90M |
| Stock buybacks / issuance | -32.10M | -24.70M | -24.90M | -76.30M | -71.60M | -74.20M |
| Ending cash balance | 122.80M | 137.40M | 93.70M | 102.90M | 163.40M | 133.50M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 23.71 | 27.19 | 19.26 | 23.46 | 16.75 | 23.64 | 24.39 | 25.07 |
| ROA %i | 5.79 | 6.35 | 4.52 | 6.17 | 4.32 | 5.96 | 7.17 | 8.29 |
| ROIC %i | 10.68 | 11.41 | 8.68 | 10.21 | 8.34 | 10.40 | 12.02 | 13.35 |
| 5-year avg ROE %i | 34.94 | 29.94 | 27.14 | 24.50 | 22.13 | 22.06 | 21.50 | 22.66 |
| EBIT margin %i | 14.97 | 15.68 | 14.14 | 16.05 | 14.41 | 15.64 | 16.51 | 18.13 |
| FCF / sales %i | 11.50 | 5.02 | 6.38 | 3.21 | 2.80 | 5.58 | 6.71 | 7.40 |
| Current ratioi | 0.98 | 1.05 | 1.32 | 1.23 | 1.25 | 1.28 | 1.05 | 1.08 |
| Quick ratioi | 0.80 | 0.83 | 1.11 | 0.75 | 0.97 | 1.04 | 0.81 | 0.83 |
| Debt / assetsi | 48.59 | 55.04 | 54.97 | 50.71 | 53.09 | 48.06 | 41.53 | 38.28 |
| LT debt / equityi | 194.14 | 241.61 | 217.90 | 178.94 | 224.49 | 175.05 | 123.31 | 108.43 |
| Interest coveragei | 4.35 | 4.52 | 3.57 | 4.99 | 3.57 | 5.23 | 6.46 | 8.74 |
| Revenue CAGR (3Y) %i | 11.14 | 8.13 | -3.05 | -2.09 | -1.89 | 10.42 | 10.20 | 10.92 |
| Net income CAGR (3Y) %i | 16.87 | 13.15 | 1.59 | 12.14 | -8.92 | 7.39 | 3.40 | 27.84 |
| FCF CAGR (3Y) %i | 12.06 | -19.14 | -9.85 | -29.54 | -19.26 | -3.74 | 28.43 | 53.39 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 25.22 | 25.24 | 24.84 | 25.07 | 25.97 | 25.40 |
| ROA %i | 7.64 | 7.89 | 8.08 | 8.29 | 8.71 | 8.70 |
| ROIC %i | 12.61 | 12.82 | 13.06 | 13.35 | 13.87 | 13.83 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.12 | 17.48 | 17.65 | 18.13 | 18.57 | 18.59 |
| FCF / sales %i | 7.01 | 7.75 | 6.95 | 7.40 | 7.66 | 6.66 |
| Current ratioi | 1.06 | 1.06 | 1.14 | 1.08 | 1.17 | 1.19 |
| Quick ratioi | 0.84 | 0.82 | 0.87 | 0.83 | 0.90 | 0.91 |
| Debt / assetsi | 40.70 | 39.58 | 38.77 | 38.28 | 38.14 | 38.11 |
| LT debt / equityi | 117.52 | 110.57 | 109.39 | 108.43 | 107.85 | 106.98 |
| Interest coveragei | 7.04 | 7.61 | 8.12 | 8.74 | 9.14 | 9.18 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Inpatient is the largest reported line at 97.13% of revenue, across 2 reported segments.
- The next-largest line, Other, is a distant second at 2.87% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Inpatient97.13%
Other2.87%
Quote time 2026-10-08 07:40:58 · For reference only, not investment advice and not tailored to your situation.